Navigation Links
Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
Date:1/18/2013

MIAMI, Jan. 18, 2013 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing.  The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally , a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs.  Biscayne also announced that it has exclusively licensed intellectual property from the University of Miami that includes worldwide rights to the Schally GHRH technology, including GHRH antagonists with potential in the treatment of cancer and GHRH agonists with potential as an innovative approach to treating heart disease.

Dr. Schally, the Distinguished Leonard M. Miller Professor of Pathology & Professor of Hematology and Oncology at the University of Miami Miller School of Medicine, was awarded the Nobel Prize in Medicine for his breakthrough work on peptide hormones and the brain.  He has had a prolific career as the inventor of many important new drugs, having discovered a number of agents based on luteinizing hormone-releasing hormone (LHRH).  Products stemming from his discoveries continue as mainstays of therapy in oncology and gynecology and generate billions of dollars in sales each year.

Dr. Schally commented, "New GHRH analogs are the latest in a line of synthetic hypothalamic hormones with potential as novel therapeutics for multiple diseases.  A number of our GHRH antagonists have demonstrated promising preclinical activity against many types of cancer, including hard-to-treat prostate cancer, and our GHRH agonists may represent a wholly new regenerative approach to treating heart disease.  GHRH analogs may also have utility in other conditions, such as Alzheimer's disease.  I look forward to working with the accomplished team at Biscayne
'/>"/>

SOURCE Biscayne Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
2. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
3. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
4. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
5. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... Hard-to-transfect Cells , Dmitriy ... Kelnar, David Brown, Ambion, Inc. , ... RNA interference (RNAi) is a powerful , ... genes. It is used routinely for gene function analysis, target , ...
... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... , open to the air--it ... or eliminate RNase contamination. However, determining which , ...
... , High Quality Custom Synthesis ... Mouse, and Rat , Genomes , ... Silencer siRNA Libraries , , ... Quality Custom RNA Synthesis by Ambion Finding a highly effective ...
Cached Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:7/23/2014)... do mollusks, starfish, and corals have in common? ... all calcifiersorganisms that use calcium from their environment ... stability and protection. , The July issue of ... Marine Biological Laboratory, addresses the challenges faced by ... As atmospheric carbon dioxide rises, the world,s oceans ...
(Date:7/23/2014)... Massachusetts , July 23, 2014 ... in its new report, GLOBAL MARKETS AND TECHNOLOGIES ... related technologies is expected to grow to nearly $154.4 ... rate (CAGR) of 10.1%. The image, flow, and level ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... fractures occur in the United States as a result of ... to rapid bone fusion but with limited mechanical strength often ... difficult to harvest without pain and severe morbidity. Funded by ... the Department of Chemistry, Chemical Biology and Biomedical Engineering at ...
... Washington two years ago launched an ambitious project harnessing the ... Foldit, turns one of the hardest problems in molecular biology ... people have now played a game that asks them to ... a princess. Results published Thursday (Aug. 5) in the ...
... shallow, nearshore waters, researchers from Stony Brook University ... first multi-year survey of the population of Antarctic ... near Livingston Island and discovered that nearshore waters ... waters. They also found that the nearshore waters ...
Cached Biology News:NSF funds innovative approach to biomimetic nanofiber bone regeneration 2NSF funds innovative approach to biomimetic nanofiber bone regeneration 3Gaming for a cure: Computer gamers tackle protein folding 2Gaming for a cure: Computer gamers tackle protein folding 3Gaming for a cure: Computer gamers tackle protein folding 4First nearshore survey of Antarctic krill reveals high density, stable population in shallow waters 2
Request Info...
FITC~Bovine Serum Albumin...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: